Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-aminocarbonyl-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide
2. R 75 231
3. R 75231
4. R 88 016
5. R 88016
6. R-75231
7. R-88016
8. R75231
1. 120770-34-5
2. R-75231
3. (s)-draflazine
4. 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
5. R 75231
6. R75231
7. 0y25dt968y
8. R-70380
9. Draflazinum
10. R70380
11. Draflazina
12. Draflazinum [inn-latin]
13. Draflazina [inn-spanish]
14. Draflazine [usan:inn:ban]
15. Unii-0y25dt968y
16. Draflazine [inn]
17. Draflazine (usan/inn)
18. Draflazine [usan]
19. (+-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
20. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-
21. Schembl215826
22. Gtpl4590
23. Chembl1628717
24. Dtxsid60869655
25. Benzenemethanesulfonylchloride, 2-methyl-
26. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)-
27. Db-057830
28. Hy-106841
29. Cs-0026695
30. Ft-0743995
31. D03906
32. Q27077112
33. (+/-)-2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazine-acetamide
34. (+/-)-4'-amino-4-(5,5-bis(p-fluorophenyl)pentyl)-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
35. 1-{[(4-amino-2,6-dichlorophenyl)carbamoyl]methyl}-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
36. 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-, (+/-)-
37. 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-1-piperazineacetamide
| Molecular Weight | 604.5 g/mol |
|---|---|
| Molecular Formula | C30H33Cl2F2N5O2 |
| XLogP3 | 5.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 11 |
| Exact Mass | 603.1979370 g/mol |
| Monoisotopic Mass | 603.1979370 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 810 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
ABOUT THIS PAGE
93
PharmaCompass offers a list of Draflazine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Draflazine manufacturer or Draflazine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Draflazine manufacturer or Draflazine supplier.
PharmaCompass also assists you with knowing the Draflazine API Price utilized in the formulation of products. Draflazine API Price is not always fixed or binding as the Draflazine Price is obtained through a variety of data sources. The Draflazine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Draflazine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Draflazine, including repackagers and relabelers. The FDA regulates Draflazine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Draflazine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Draflazine supplier is an individual or a company that provides Draflazine active pharmaceutical ingredient (API) or Draflazine finished formulations upon request. The Draflazine suppliers may include Draflazine API manufacturers, exporters, distributors and traders.
click here to find a list of Draflazine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Draflazine DMF (Drug Master File) is a document detailing the whole manufacturing process of Draflazine active pharmaceutical ingredient (API) in detail. Different forms of Draflazine DMFs exist exist since differing nations have different regulations, such as Draflazine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Draflazine DMF submitted to regulatory agencies in the US is known as a USDMF. Draflazine USDMF includes data on Draflazine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Draflazine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Draflazine suppliers with USDMF on PharmaCompass.
Draflazine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Draflazine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Draflazine GMP manufacturer or Draflazine GMP API supplier for your needs.
A Draflazine CoA (Certificate of Analysis) is a formal document that attests to Draflazine's compliance with Draflazine specifications and serves as a tool for batch-level quality control.
Draflazine CoA mostly includes findings from lab analyses of a specific batch. For each Draflazine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Draflazine may be tested according to a variety of international standards, such as European Pharmacopoeia (Draflazine EP), Draflazine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Draflazine USP).
